SCHEMBL3286549

SCHEMBL3286549

Cc1cc(CO)sn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20320618 0.74
SCHEMBL22367354 0.74 AGBL2 (0.36)
SCHEMBL8119362 0.73
SCHEMBL20320474 0.73 NOS3 (0.33)
SCHEMBL7174681 0.71 ALDH1A1 (0.31)
SCHEMBL22367369 0.71
SCHEMBL8450139 0.71
SCHEMBL22367351 0.66
SCHEMBL17825204 0.66 GABRA1 (0.32)
SCHEMBL10960911 0.66 L3MBTL1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037339-B2 Substituted imidazoles as GLP-1 receptor agonists ECCOGENE INC. (US) 2024-07-16 US disclosed
US-11242344-B2 (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof GENENTECH, INC. (US) 2022-02-08 US disclosed
US-11242344-B2 (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof GENENTECH, INC. (US) 2022-02-08 US disclosed
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-10-07 US disclosed
US-20210309660-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF GENENTECH INC (US) 2021-10-07 US disclosed
EP-3700901-A1 (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF Genentech, Inc. (US) 2020-09-02 EP disclosed
EP-2432776-B1 METHYL SULFANYL PYRIMIDINES USEFUL AS ANTIINFLAMMATORIES, ANALGESICS, AND ANTIEPILEPTICS UNIV LAVAL (CA) 2019-09-11 EP disclosed
US-10239843-B2 2,4-dioxo-quinazoline-6-sulfonamide derivatives as inhibitors of PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-03-26 US disclosed
US-20180016242-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-01-18 US disclosed
EP-3230273-A1 2,4-DIOXO-QUINAZOLINE-6-SULFONAMIDE DERIVATIVES AS INHIBITORS OF PARG Cancer Research Technology Ltd (GB) 2017-10-18 EP disclosed
JP-2005082486-A 3-METHYLISOTHIAZOLE-5-METHANOL DERIVATIVE, METHOD FOR PRODUCING THE SAME AND AGRICULTURAL AND HORTICULTURAL DISEASE INJURY CONTROLLING AGENT KUREHA CHEM IND CO LTD 2005-03-31 JP disclosed
US-20040235822-A1 Benzazepine derivative, process for producing the same, and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2004-11-25 US disclosed
EP-1451161-A1 IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS Merck Sharp &amp; Dohme Limited (GB) 2004-09-01 EP disclosed
EP-1422228-A1 BENZAZEPINE DERIVATIVE&amp;comma; PROCESS FOR PRODUCING THE SAME&amp;comma; AND USE Takeda Chemical Industries, Ltd. (JP) 2004-05-26 EP disclosed
WO-2003048132-A1 IMIDAZOPYRIDINES, PYRIMIDINES AND TRIAZINES FOR ENHANCING COGNITION AS GABA-A ALPHA 5 RECEPTOR SUBTYPE LIGANDS MERCK SHARP & DOHME LIMITED (GB) 2003-06-12 WO disclosed
EP-0588917-B1 ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LAB (US) 2000-11-08 EP disclosed
US-5409946-A Antiepileptic agent ABBOTT LABORATORIES (US) 1995-04-25 US disclosed
EP-0588917-A4 1994-04-13 EP disclosed
EP-0588917-A1 ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LABORATORIES (US) 1994-03-30 EP disclosed
WO-1992021339-A1 ISOXAZOLE AND ISOTHIAZOLE COMPOUNDS THAT ENHANCE COGNITIVE FUNCTION ABBOTT LABORATORIES (US) 1992-12-10 WO disclosed